Mrinal M. Gounder

Oncology

160 E 53rd St
New York, NY 10022

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 127 publications

BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies.

BRIGHTLINE-1: When a Negative Trial Reveals Two Active Therapies.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 06, 2026

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.

Natural history and treatment outcomes in aggressive angiomyxoma: A single institution experience.

Journal: European journal of cancer (Oxford, England : 1990)

Published: June 27, 2026

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: April 24, 2026

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Phase 2 study of palbociclib plus retifanlimab in patients with advanced dedifferentiated liposarcoma.

Journal: Journal for immunotherapy of cancer

Published: April 15, 2026

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Concomitant Medication Effects on Immunotherapy Outcomes in Sarcoma: A Pooled Post Hoc Analysis of Seven Phase II Trials.

Journal: Cancer medicine

Published: April 08, 2026

Molecular profiling of sacral chordomas through methylation, spatial transcriptomics and multiplexed immunofluorescence.

Molecular profiling of sacral chordomas through methylation, spatial transcriptomics and multiplexed immunofluorescence.

Journal: ESMO rare cancers

Published: April 02, 2026

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.

Overall survival from the open-label phase II trial of palbociclib in patients with advanced well-differentiated/dedifferentiated liposarcoma.

Journal: ESMO open

Published: October 29, 2025

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Efficacy and Safety of Long-Term Continuous Nirogacestat Treatment in Adults With Desmoid Tumors: Results From the DeFi Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: October 20, 2025

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 10, 2025

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.

Repurposing nirogacestat, a gamma secretase enzyme inhibitor in desmoid tumors.

Journal: Future oncology (London, England)

Published: September 01, 2025

High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.

High transposable element expression in sarcomas is associated with increased immune infiltrates and improved outcomes including after immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: July 16, 2025

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Tumor and Immune Dynamics Following Sequential CDK4/6 and PD-1 Inhibition: Results from a Phase 2 Study in Dedifferentiated Liposarcoma.

Journal: Cancer research communications

Published: June 25, 2025

Showing 1-12 of 127

Last Updated: 09/26/2026